8-K: Orgenesis Stock Downgraded to Expert Market Amidst 10-K Filing Delinquency

Orgenesis Inc.'s common stock has been moved to the OTC Markets Expert Market tier due to a significant delay in filing its annual 10-K report.

Summary

• OTC Markets Group notified Orgenesis Inc. on July 29, 2025, of its decision to move the company's common stock from the Pink Limited tier to the Expert Market tier, effective immediately.
• The downgrade is a direct consequence of Orgenesis Inc. being more than 180 days delinquent in filing its 10-K report for the period ending December 31, 2024.
• The company is no longer in compliance with SEC Rule 15c2-11 due to this filing delinquency.
• Orgenesis Inc. was unable to remedy the deficiency within the 15-day cure period provided by OTC Markets.

Sentiment

Score: 2

Explanation: The filing indicates severe compliance issues, including a significant delay in a mandatory SEC filing and a downgrade to a less transparent market tier, which are highly negative for investor confidence and stock liquidity.

Negatives

• Orgenesis Inc. common stock was downgraded from the Pink Limited tier to the Expert Market tier by OTC Markets Group.
• The company is more than 180 days delinquent in filing its 10-K for the period ending December 31, 2024.
• Orgenesis Inc. is no longer in compliance with SEC Rule 15c2-11.
• The company failed to remedy the filing deficiency within the 15-day cure period.

Risks

• Reduced liquidity and trading activity for the company's common stock due to its placement on the Expert Market tier.
• Decreased investor confidence and potential difficulty in attracting new investors due to non-compliance with SEC filing requirements.
• Potential for further regulatory actions or penalties from the SEC due to ongoing non-compliance.
• Limited public information available to investors as companies on the Expert Market tier are not required to make current information publicly available through OTC Markets.

Future Outlook

No explicit forward-looking statements or guidance were provided in the filing regarding future operations or financial performance.

Management Comments

• The report was signed by Victor Miller, Chief Financial Officer, Treasurer and Secretary of Orgenesis Inc.

Industry Context

The move to the OTC Markets Expert Market tier signifies a severe compliance issue for a publicly traded company. Companies on this tier typically have limited public disclosure and are not subject to the same reporting requirements as those on higher tiers, which can significantly impact investor confidence and stock liquidity. This situation is a red flag for corporate governance and transparency within the biotechnology or healthcare industry, where timely and accurate financial reporting is crucial for investor trust.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience reduced liquidity and transparency for their shares due to the move to the Expert Market tier, potentially impacting the stock's value and ease of trading.
• Potential Investors: May be deterred from investing due to the lack of timely financial information and the company's non-compliance with SEC regulations.
• Regulatory Authorities: The SEC and OTC Markets Group have taken action due to non-compliance, indicating potential for further regulatory scrutiny or penalties.

Key Dates

Recommendation

The company's failure to file its annual 10-K report for over 180 days and subsequent downgrade to the OTC Expert Market tier represent severe red flags. This indicates a critical breakdown in financial reporting and corporate governance, leading to a significant loss of transparency and liquidity. Such non-compliance typically erodes investor confidence, making the stock highly speculative and risky. A seasoned investor would likely divest to avoid further potential losses and exposure to a company with such fundamental operational and regulatory issues.

Keywords

Orgenesis, ORGS, SEC, 8-K, OTC Markets, Expert Market, Pink Limited, 10-K, delinquency, compliance, regulatory, stock downgrade